FCGR2A and cancer: However, limitations specifically affecting IgG-based antibodies such as low affinity for Fcγ receptors (FcγR); FcγR polymorphisms that influence IgG affinity and effector function potency; and engagement of the inhibitor receptor FcγRIIB, which dampens pro-inflammatory signaling, can affect their potency against specific cancers [7,8,9,10,11].